Spinal Muscular Atrophy (SMA) Treatment Market Trends, Size, Competitive Analysis and Forecast - 2019-2025
The global spinal muscular atrophy
(SMA) treatment market is projected to exhibit considerable
growth during the forecast period. The high prevalence of this disorder, a
rapid rise in the R&D activities related to the development of therapies
and treatment options by the major market players is a major factor anticipated
to fuel the market during the forecast period. Biogen, Inc., Ionis
Pharmaceuticals, Inc., Pfizer, Inc., F. Hoffmann-La Roche AG, Cytokinetics,
Inc., PRA Health Sciences Inc., Cure SMA, Boston Scientific Corp. and so on are
the key market players operating in the global market.
A full Report of Global Spinal Muscular
Atrophy (SMA) Treatment Market Available
at https://www.omrglobal.com/industry-reports/spinal-muscular-atrophy-sma-treatment-market
These market
players are making hefty investments in their R&D sector to introduce new
products and to perform technological advancement in their existing product
offerings. For instance,in November 2019, H. Hoffman La Roche confirmed that the
US FDA had approved the New Drug Application (NDA) submitted by the company and
granted a priority review for risdiplam, an SMA splicing modification for the
investigational survival motor neuron-2 (SMN-2). Risdiplam is engineered to
increase and maintain SMA protein levels in the body's central nervous system
as well as peripheral tissues. The FDA is expected to approve the drug by the
end of May 2020.
Request a Free Report on Sample of Global
Spinal Muscular Atrophy (SMA) Treatment Market @ https://www.omrglobal.com/request-sample/spinal-muscular-atrophy-sma-treatment-market
In September
2019, Biogen Inc. has made advancement in the SMA clinical research with the
initiation of a new study to evaluate a higher dose of spinraza
(nusinersen) and additional data in a broad range of patients. In addition, In
May 2019, Avexis had received the FDA approval forits first gene therapy, Zolgensma
(onasemnogeneabeparvovec-xioi). This therapy is used to treat children less
than two years of age with spinal muscular atrophy (SMA). The SMA that occurs
under this age is the most critical form of SMA and is the major genetic cause
of infant mortality. Thus, the increasing FDA approval for the drugs and
therapy for the treatment of SMA is anticipated to be a major factor to drive
the growth of the global SMA treatment market.
Current Market Trends Covered in the Market
Report
·
The rapid increase in technological innovation
and product development related to SMA.
·
North America is anticipated to hold a major
market share during the forecast period.
·
The rising awareness among people related to the
treatment of the disease to create an opportunity for the mar market growth.
·
Partnerships and collaborations – key drivers of
competition in the SMA market.
Global Spinal Muscular Atrophy (SMA) Market
Segmentation
By Treatment Type
·
Gene Therapy
·
Medication
By Disease Type
·
Type l
·
Type ll
·
Type lll
·
Type lV
Segmentation by region
North America
·
United States
·
Canada
Europe
·
UK
·
Germany
·
Italy
·
Spain
·
France
·
Rest of Europe
Asia-Pacific
·
China
·
Japan
·
India
·
Rest of the Asia-Pacific
Rest of the World
·
Middle East & Africa
·
Latin America
For More Customized Data, Request for Report
Customization @ https://www.omrglobal.com/report-customization/spinal-muscular-atrophy-sma-treatment-market
About Orion Market Research
Orion
Market Research (OMR) is a market research and consulting company known for its
crisp and concise reports. The company is equipped with an experienced team of
analysts and consultants. OMR offers quality syndicated research reports,
customized research reports, consulting and other research-based services.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. AnuragTiwari
Contact no: +1 646-755-7667, +91 780-304-0404
Comments
Post a Comment